GLP-1 Medications by Condition

GLP-1 receptor agonists are FDA-approved for a growing list of chronic conditions beyond type 2 diabetes. As of April 2026, specific GLP-1 drugs are indicated for type 2 diabetes, chronic weight management, cardiovascular risk reduction, obstructive sleep apnea, and — under FDA review — metabolic dysfunction-associated steatohepatitis (MASH). Different drugs in the class carry different approved indications: semaglutide (Wegovy) is approved for cardiovascular risk reduction, while tirzepatide (Zepbound) is approved for obstructive sleep apnea. Not every GLP-1 is approved for every condition, and off-label use carries insurance and safety implications. The guides below examine each condition, which drug is FDA-approved for it, what the pivotal trials showed, and what patients should discuss with their clinician before starting treatment.